Metrics as of 10/14/2026, 06:01 AM (Berlin time), refresh in progress.
Tango Therapeutics Stock
Tango Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Malte Peters
- Employees
- 137
- Market cap
- $3.6 B
- IPO
- 03/09/2020
Tango Therapeutics, Inc. is a biotechnology company operating within the healthcare sector and is headquartered in Boston, USA. Established in 2017, the firm maintains its operations in Cambridge, Massachusetts, and employs approximately 137 employees. The company focuses on the research and development of innovative…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Tango Therapeutics stock: price history
1D
-8.1%
1W
+1.5%
1M
-6.6%
6M
-7.6%
YTD
+150.8%
1Y
+162.3%
2Y
+223.9%
5Y
+57.5%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~80% stronger price swings than usual
Ask the agents about Tango Therapeutics
Analyst assessment of Tango Therapeutics
PRICE TARGET LOW
US$24.00
CONSENSUS
US$45.91
MEDIAN
US$40.00
PRICE TARGET HIGH
US$69.00
0
STRONG BUY
12
BUY
1
HOLD
0
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 18/08/2026
Tango Therapeutics stock metrics
P/E
-26.14
P/B
3.25
EV/EBITDA
-27.11
RETURN ON EQUITY
-5.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
65.3%
FLOAT SHARES
106,263,163
AVG. DAILY VOLUME (30D)
3,375,889
Insider transactions (SEC)
Crystal Adam
Crystal Adam
Crystal Adam
Newcomb Jessica
Newcomb Jessica
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -8.1%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Tango Therapeutics stock
What does Tango Therapeutics do?
Tango Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Malte Peters, the company employs around 137 people.
The IPO was on 03/09/2020; the stock trades on NASDAQ under the ticker TNGX.
What do analysts say about Tango Therapeutics stock?
13 analysts rate the stock, the consensus is Buy (as of 18/08/2026).
The average price target is US$45.91, ranging from US$24.00 to US$69.00, with a median of US$40.00.
This is an external assessment, not a statement by Market Jury.
When does Tango Therapeutics report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 80% stronger than usual.
Does Tango Therapeutics pay a dividend?
No, Tango Therapeutics currently does not pay a dividend.
Which stocks are comparable to Tango Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Tango Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Tango Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.